CRC01

CRC01 is a CAR-T cell therapy developed by Curocell. Its target is CD19 (the sponsor names CD19). The sponsor states: A single intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells directed against CD19, engineered with PD-1 and TIGIT knock-down to enhance T-cell effector function, given after fludarabine/cyclophosphamide conditioning. ClinicalTrials.gov describes the intervention as: Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-t. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. The largest, NCT04836507, plans to enrol 91 participants with primary completion expected 2030-08-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.